Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Livagen
Also known as: Lys-Glu-Asp-Ala, KEDA
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator research program, designed as a liver and immune system bioregulator. In vitro studies suggest it can decondense chromatin in hepatocyte and lymphocyte nuclei, potentially reactivating silenced genes. Human evidence is limited to small Russian studies.
Risk Level
Medium RiskDifficulty
Advanced| Molecular Formula | C17H29N4O9 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to interact directly with heterochromatin in hepatocyte and lymphocyte nuclei, causing chromatin decondensation and reactivation of gene transcription. This epigenetic mechanism theoretically restores age-related gene silencing in liver and immune cells, improving their functional capacity.
Dosing Research
Typically administered as 10 mg capsules, 1-2 daily for 10-30 days. Intramuscular injection protocols also exist. Often combined with other bioregulators targeting different organ systems. Courses repeated every 3-6 months.
Side Effects & Risks
Minimal adverse effects reported in available literature. Theoretical concern that chromatin-modifying agents could have unpredictable epigenetic consequences. No controlled safety studies available. The short peptide is rapidly degraded in vivo.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.